HRMY
Harmony Biosciences Holdings, Inc.Company Information
- Company Name
- Harmony Biosciences Holdings, Inc.
- CIK
- CIK0001802665
- Category
- Large accelerated filer
- Ticker: Exchange
- HRMY: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- HRMY
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-18
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 138,373
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 49,950,677
- Shares outstanding
- 57,933,818
- Ownership
- 86.22%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 1.11%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 550 | 589 | 753 | 647 | 546 | 489 | 453 | 387 | 317 | 333 | 312 | 325 | ||||||
| Short Term Investments | 118 | 52 | 23 | 26 | 19 | 18 | 14 | 23 | 30 | 39 | 42 | 46 | ||||||
| Accounts Receivable Net Current | 111 | 108 | 97 | 101 | 93 | 106 | 83 | 82 | 83 | 80 | 74 | 67 | ||||||
| Inventory Net | 6 | 5 | 5 | 7 | 6 | 6 | 7 | 7 | 6 | 6 | 5 | 5 | ||||||
| Prepaid Expense Current | 19 | 17 | 16 | 23 | 18 | 16 | 14 | 16 | 16 | 13 | 13 | 14 | ||||||
| Other Assets Current | 10 | 8 | 14 | 35 | 9 | 7 | 8 | 7 | 7 | 9 | 6 | 6 | ||||||
| Assets Current | 814 | 779 | 907 | 839 | 691 | 643 | 579 | 522 | 458 | 480 | 451 | 463 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Long Term Investments | 295 | 230 | 107 | 106 | 107 | 103 | 109 | 94 | 87 | 81 | 72 | 68 | ||||||
| Restricted Cash Noncurrent | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 77 | 83 | 89 | 95 | 101 | 107 | 113 | 119 | 125 | 131 | 137 | 143 | ||||||
| Deferred Income Tax Assets Net | 157 | 154 | 150 | 157 | 201 | 195 | 190 | 185 | 180 | 148 | 144 | 100 | ||||||
| Other Assets Noncurrent | 30 | 26 | 18 | 10 | 5 | 6 | 7 | 6 | 6 | 7 | 6 | 3 | ||||||
| Assets Noncurrent | 559 | 493 | 365 | 369 | 417 | 413 | 420 | 406 | 400 | 367 | 360 | 315 | ||||||
| Assets | 1,373 | 1,272 | 1,272 | 1,208 | 1,108 | 1,056 | 999 | 928 | 858 | 847 | 811 | 778 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 22 | 29 | 18 | 26 | 28 | 17 | 14 | 11 | 23 | 15 | 18 | 7 | ||||||
| Employee Related Liabilities Current | 12 | 7 | 18 | 15 | 12 | 8 | 19 | 14 | 10 | 7 | 24 | 10 | ||||||
| Accrued Liabilities Current | 169 | 150 | - | - | - | - | - | - | - | - | - | 73 | ||||||
| Long Term Debt Current | 20 | 20 | 20 | 20 | 19 | 18 | 16 | 15 | 15 | 15 | 15 | 15 | ||||||
| Other Liabilities Current | 11 | 12 | 5 | 1 | 3 | 20 | 6 | 12 | 8 | 25 | 8 | 8 | ||||||
| Liabilities Current | 234 | 217 | 252 | 223 | 180 | 175 | 175 | 161 | 147 | 154 | 164 | 112 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Debt Noncurrent | 134 | 139 | 144 | 149 | 153 | 158 | 163 | 168 | 171 | 175 | 179 | 182 | ||||||
| Other Liabilities Noncurrent | 6 | 5 | 6 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Noncurrent | 140 | 144 | 149 | 150 | 155 | 160 | 165 | 170 | 173 | 177 | 181 | 184 | ||||||
| Liabilities | 374 | 361 | 401 | 373 | 335 | 335 | 340 | 331 | 320 | 332 | 344 | 296 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 731 | 717 | 709 | 696 | 685 | 673 | 657 | 644 | 632 | 621 | 610 | 652 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | 269 | 193 | 161 | 138 | 88 | 48 | 2 | -47 | -93 | -105 | -143 | -170 | ||||||
| Stockholders Equity | 999 | 910 | 870 | 835 | 773 | 721 | 659 | 597 | 539 | 515 | 467 | 481 | ||||||
| Liabilities And Stockholders Equity | 1,373 | 1,272 | 1,272 | 1,208 | 1,108 | 1,056 | 999 | 928 | 858 | 847 | 811 | 778 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 58 | 58 | 58 | 58 | 58 | 57 | 57 | 57 | 57 | 57 | 57 | 59 | ||||||
| Shares Outstanding | 58 | 58 | 58 | 58 | 58 | 57 | 57 | 57 | 57 | 57 | 57 | 59 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHarmony Biosciences Holdings, Inc. (HRMY) — SEC Financial Statements & Analysis
Harmony Biosciences Holdings, Inc. (HRMY) is a pharmaceutical preparations company, incorporated in DE. Harmony Biosciences Holdings, Inc. trades on Nasdaq as: HRMY. Harmony Biosciences Holdings, Inc. (HRMY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Harmony Biosciences Holdings, Inc. carries a market cap of $2.11B, a P/E ratio of 11.64x, a P/B ratio of 2.11x, a P/S ratio of 2.20x, an enterprise value of $1.71B, and an EV/EBITDA multiple of 7.24x. On profitability, it posts a gross margin of 75.42%, an operating margin of 24.03%, a net margin of 18.88%, a Return on Equity (ROE) of 20.46%, a Return on Assets (ROA) of 14.61%, and a Return on Invested Capital (ROIC) of 33.44%. Per share, it reports EPS of $3.13, diluted EPS of $3.09, free cash flow per share of $6.12, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 24.25% year-over-year, net income growth of 0.20% year-over-year, and EPS growth of -0.60% year-over-year. On the balance sheet, it maintains a current ratio of 3.48x, a quick ratio of 3.37x, working capital of $580.26M, a debt-to-equity ratio of 0.37x, a debt ratio of 0.27, an interest coverage ratio of 17.12x, free cash flow of $354.77M (TTM), and net debt of $-396.08M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.11B
- P/E TTM
- 11.64x
- EPS TTM
- $3.13
- P/B TTM
- 2.11x
- ROE TTM
- 20.46%
- ROA TTM
- 14.61%
- Debt To Equity
- 0.37x
- Free Cash Flow TTM
- $354.77M
- Net Revenue TTM Growth 1Y
- 24.25%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Harmony Biosciences Holdings, Inc. in?
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Pharmaceutical Preparations industry.
What exchange does HRMY trade on?
Harmony Biosciences Holdings, Inc. (HRMY) trades on the Nasdaq.
Where is Harmony Biosciences Holdings, Inc. incorporated?
Harmony Biosciences Holdings, Inc. is incorporated in DE.
When was Harmony Biosciences Holdings, Inc. (HRMY)'s most recent SEC filing?
Harmony Biosciences Holdings, Inc. (HRMY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is HRMY's market cap?
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.11B as of 2026-06-30.
What is HRMY's P/E ratio?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month P/E ratio is 11.64x as of 2026-06-30.
What is HRMY's EPS (earnings per share)?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month EPS is $3.13 as of 2026-06-30.
What is HRMY's ROE (return on equity)?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month Return on Equity (ROE) is 20.46% as of 2026-06-30.
What is HRMY's ROA (return on assets)?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month Return on Assets (ROA) is 14.61% as of 2026-06-30.
What is HRMY's ROIC (return on invested capital)?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month Return on Invested Capital (ROIC) is 33.44% as of 2026-06-30.
What is HRMY's EV/EBITDA?
Harmony Biosciences Holdings, Inc. (HRMY)'s trailing twelve month EV/EBITDA is 7.24x as of 2026-06-30.